Aim: Aim of the study was to evaluate efficacy and tolerability of gabapentin (GBP) in the prophylaxis of Bipolar Disorders. Material and methods: 21 patients, affected by Bipolar Disorders in partial remission, intollerant or non compliant to other treatments, were treated with GBP at a mean dose of 1010.86 mg/die for a year. Clinical evaluation was performed by BPRS, HRSD, HRSA and MRS administered at T0, after 15 days (T0.5), one month (T1) and then every month for one year (T12). Haemocrome with leukocytes count was evaluated at T0, after 6 months (T6) and at the end of the study. A check list for side effects was noted. Results: Three patients have dropped out the treatment after 2 weeks, one after 6 months, an for no compliance, and one patient for inefficacy (manic shift). Rating scales mean values did not show any significant variation during the study. The most frequently reported side effects were dizziness (1%), dry mouth (1%) and sedation (0.5%). A negative significant correlation between GBP dose (mg/kg) and HRSA mean values resulted. Discussion: These data seem to suggest that GBP was able to stabilize the clinical picture of patients. The negative relationship between GBP dose (mg/kg) and HRSA mean values may be attributed to GBP anxiolitic properties. GBP showed a good tolerability because of low side effects incidence. In conclusion, GBP seems to have a good efficacy and tolerability, in monotherapy, in the prophylaxis of Bipolar Disorders, double blind studies being advisable.
|Translated title of the contribution||Efficacy and tolerability of gabapentin in the prophylaxis of bipolar disorders|
|Number of pages||4|
|Journal||Rivista di Psichiatria|
|Publication status||Published - 1999|
ASJC Scopus subject areas
- Psychiatry and Mental health